
Jianguo Sun

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/102772/publications.pdf Version: 2024-02-01



Ιμνισμό Σιμν

#	Article	IF	CITATIONS
1	Fingerprint loss during combination therapy using osimertinib and anlotinib: A case report. Journal of Clinical Pharmacy and Therapeutics, 2022, 47, 248-250.	1.5	2
2	Efficacy and safety of recombinant human endostatin during peri-radiotherapy period in advanced non-small-cell lung cancer. Future Oncology, 2022, 18, 1077-1087.	2.4	7
3	Immune Response on Optimal Timing and Fractionation Dose for Hypofractionated Radiotherapy in Non–Small-Cell Lung Cancer. Frontiers in Molecular Biosciences, 2022, 9, 786864.	3.5	5
4	Rapid Progress in Intelligent Radiotherapy and Future Implementation. Cancer Investigation, 2022, 40, 425-436.	1.3	6
5	Efficacy and safety of low-dose radiotherapy (LDRT) concurrent atezolizumab plus chemotherapy as first-line therapy for ES-SCLC : Interim analysis of Phase II MATCH trial Journal of Clinical Oncology, 2022, 40, e20611-e20611.	1.6	3
6	Differences between primary peritoneal serous carcinoma and advanced serous ovarian carcinoma: a study based on the SEER database. Journal of Ovarian Research, 2021, 14, 40.	3.0	3
7	Case Report: Long-Term Response to Pembrolizumab Combined With Endocrine Therapy in Metastatic Breast Cancer Patients With Hormone Receptor Expression. Frontiers in Immunology, 2021, 12, 610149.	4.8	5
8	Attitudes and Practices of Immune Checkpoint Inhibitors in Chinese Patients With Cancer: A National Cross-Sectional Survey. Frontiers in Pharmacology, 2021, 12, 583126.	3.5	2
9	Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients. Frontiers in Immunology, 2021, 12, 665133.	4.8	41
10	Survival Analysis and Prediction Model for Pulmonary Sarcomatoid Carcinoma Based on SEER Database. Frontiers in Oncology, 2021, 11, 630885.	2.8	22
11	The Efficacy and Safety of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Thymosin in Advanced Non-Small Cell Lung Cancer Patients Harboring Active Epidermal Growth Factor Receptor Mutations. Frontiers in Oncology, 2021, 11, 659065.	2.8	3
12	Factors for incidence risk and prognosis in non-small-cell lung cancer patients with synchronous brain metastasis: a population-based study. Future Oncology, 2021, 17, 2461-2473.	2.4	6
13	Clinical features and death risk factors in COVID-19 patients with cancer: a retrospective study. BMC Infectious Diseases, 2021, 21, 760.	2.9	4
14	Clinical characteristics and a decision tree model to predict death outcome in severe COVID-19 patients. BMC Infectious Diseases, 2021, 21, 783.	2.9	14
15	Indications for and contraindications of immune checkpoint inhibitors in cancer patients with COVID-19 vaccination. Future Oncology, 2021, 17, 3477-3484.	2.4	23
16	Optimization of aÂprotocol for contrast-enhanced four-dimensional computed tomography imaging of thoracic tumors using minimal contrast agent. Strahlentherapie Und Onkologie, 2021, 197, 1021-1031.	2.0	0
17	Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States. JAMA Network Open, 2021, 4, e2124750.	5.9	98
18	A randomized, controlled phase II trial of maxillofacial and oral massage in attenuating severe radiotherapy-induced oral mucositis and lipid metabolite changes in nasopharyngeal carcinoma. Radiotherapy and Oncology, 2021, 163, 76-82.	0.6	4

JIANGUO SUN

#	Article	IF	CITATIONS
19	Association of Radioiodine for Differentiated Thyroid Cancer and Second Breast Cancer in Female Adolescent and Young Adult. Frontiers in Endocrinology, 2021, 12, 805194.	3.5	5
20	Allele Frequency–Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors. Journal of Thoracic Oncology, 2020, 15, 556-567.	1.1	66
21	Oncogenic miR-20b-5p contributes to malignant behaviors of breast cancer stem cells by bidirectionally regulating CCND1 and E2F1. BMC Cancer, 2020, 20, 949.	2.6	22
22	Identification of a prognostic immune-related signature for small cell lung cancer Journal of Clinical Oncology, 2020, 38, e21041-e21041.	1.6	0
23	Concurrent somatic alterations of TP53 and RB1 in Chinese lung adenocarcinoma with or without EGFR mutations Journal of Clinical Oncology, 2020, 38, e21526-e21526.	1.6	0
24	Construction of nomograms for nasopharyngeal carcinoma containing primary tumor size and SEER stage. Translational Cancer Research, 2020, 9, 6939-6954.	1.0	6
25	Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial. Clinical Cancer Research, 2019, 25, 6967-6975.	7.0	52
26	Clinical associations and prognostic value of site‑specific metastases in non‑small cell lung cancer: A population‑based study. Oncology Letters, 2019, 17, 5590-5600.	1.8	22
27	Concurrent EGFR-TKI and Thoracic Radiotherapy as First-Line Treatment for Stage IV Non-Small Cell Lung Cancer Harboring EGFR Active Mutations. Oncologist, 2019, 24, 1031-e612.	3.7	48
28	Rab25 promotes erlotinib resistance by activating the β1 integrin/AKT/β atenin pathway in NSCLC. Cell Proliferation, 2019, 52, e12592.	5.3	36
29	Clinicopathological characteristics and prognostic factors of pulmonary large cell neuroendocrine carcinoma: A large populationâ€based analysis. Thoracic Cancer, 2019, 10, 751-760.	1.9	23
30	Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel. JAMA Oncology, 2019, 5, 696.	7.1	380
31	<p>Hyperprogressive Disease In Cervical Small Cell Carcinoma Treated By Immune Checkpoint Inhibitor</p> . OncoTargets and Therapy, 2019, Volume 12, 8873-8877.	2.0	10
32	Combination of metformin and gefitinib as first-line therapy for nondiabetic advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations: A multicenter, randomized, double-blind, placebo-controlled phase II trial Journal of Clinical Oncology, 2019, 37, 9035-9035.	1.6	1
33	Clinical benefits of Livin peptide-loaded DCs/CIKs combined with chemotherapy in advanced non-small cell lung cancer. American Journal of Cancer Research, 2019, 9, 406-414.	1.4	6
34	A dosimetric phantom study of thoracic radiotherapy based on three-dimensional modeling of mediastinal lymph nodes. Oncology Letters, 2018, 15, 5634-5642.	1.8	0
35	Radiosensitizing effects of miRâ€18aâ€5p on lung cancer stemâ€like cells via downregulating both <scp>ATM</scp> and <scp>HIF</scp> â€1α. Cancer Medicine, 2018, 7, 3834-3847.	2.8	53
36	Phosphatase and tensin homolog deleted on chromosome 10 degradation induced by NEDD4 promotes acquired erlotinib resistance in non–small-cell lung cancer. Tumor Biology, 2017, 39, 101042831770963.	1.8	15

JIANGUO SUN

#	Article	IF	CITATIONS
37	Induced cancer stem cells generated by radiochemotherapy and their therapeutic implications. Oncotarget, 2017, 8, 17301-17312.	1.8	64
38	A case report: delayed high fever and maculopapules during Sorafenib treatment of ectopic hepatocellular carcinoma. BMC Cancer, 2016, 16, 543.	2.6	8
39	miR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway. International Journal of Oncology, 2016, 48, 1855-1867.	3.3	56
40	Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer. Tumor Biology, 2016, 37, 11927-11936.	1.8	68
41	IGFBP7 functions as a potential lymphangiogenesis inducer in non-small cell lung carcinoma. Oncology Reports, 2016, 35, 1483-1492.	2.6	11
42	Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer. Radiation Oncology, 2016, 11, 60.	2.7	18
43	Clinical benefit from EGFR-TKI plus ginsenoside Rg3 in patients with advanced non-small cell lung cancer harboring EGFR active mutation. Oncotarget, 2016, 7, 70535-70545.	1.8	28
44	Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes. Cancer Letters, 2015, 369, 97-102.	7.2	82
45	Inhibitory effect of endostatin combined with paclitaxel-cisplatin on breast cancer in xenograft-bearing mice. Experimental and Therapeutic Medicine, 2012, 3, 159-164.	1.8	9
46	Evaluation of Traffic Injury Prevention Programs Using Counting Process Approaches. Journal of the American Statistical Association, 2001, 96, 469-475.	3.1	9